almagate has been researched along with Disease Exacerbation in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amantea, M; Basile, AS; Johnson, TR; Klamerus, KJ; Nickens, DJ; Sultan, MB; Zhou, D | 1 |
| Goverdhan, S; Krishnan, R; Lochhead, J | 1 |
| Morrow, T | 1 |
| Spires, RA | 1 |
| Adamis, AP; Lu, M | 1 |
| Fekrat, S; Williams, AJ | 1 |
| Del Priore, LV; Shah, AR | 1 |
| Clegg, AJ; Colquitt, J; Jones, J; Takeda, AL | 1 |
| Adán, A; Casaroli-Marano, RP | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H; van Meurs, JC | 1 |
5 review(s) available for almagate and Disease Exacerbation
| Article | Year |
|---|---|
How you can help when older eyes fail.
Topics: Age Distribution; Aged; Aptamers, Nucleotide; Causality; Disease Progression; Humans; Laser Coagulation; Macular Degeneration; Middle Aged; Nurse's Role; Nursing Assessment; Patient Education as Topic; Photochemotherapy; Referral and Consultation; Risk Assessment; United States; Visual Acuity | 2006 |
Molecular biology of choroidal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Biomarkers; Choroid; Choroidal Neovascularization; Disease Progression; Humans; Injections; Molecular Biology; Ranibizumab; Vascular Endothelial Growth Factor A; Vitreous Body | 2006 |
Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Blindness; Choroidal Neovascularization; Disease Progression; Exudates and Transudates; Humans; Macula Lutea; Macular Degeneration; Photochemotherapy; Pregnadienediols; Randomized Controlled Trials as Topic; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Progression; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
[New drugs; pegaptanib and ranibizumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Disease Progression; Humans; Macular Degeneration; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2008 |
5 other study(ies) available for almagate and Disease Exacerbation
| Article | Year |
|---|---|
Integrating disease progression models, non-clinical pharmacokinetic data and treatment response endpoints to optimize intravitreal dosing regimens.
Topics: Aptamers, Nucleotide; Disease Progression; Humans; Intravitreal Injections; Models, Biological; Vascular Endothelial Growth Factor A; Visual Acuity | 2014 |
Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment.
Topics: Adult; Aptamers, Nucleotide; Diabetic Retinopathy; Disease Progression; Female; Humans; Intravitreal Injections; Middle Aged; Retinal Detachment; Visual Acuity | 2009 |
Aptamers: slowing progression of AMD.
Topics: Age Factors; Aptamers, Nucleotide; Disease Progression; Humans; Macular Degeneration; Oligonucleotides; United States; Vision, Ocular | 2005 |
Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Progression; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Middle Aged; Vascular Endothelial Growth Factor A; Vitreous Body | 2006 |
[New therapeutic aspects in age-related macular degeneration].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Clinical Trials, Phase III as Topic; Disease Progression; Forecasting; Humans; Macular Degeneration; Middle Aged; Multicenter Studies as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Risk Factors; Smoking; Smoking Cessation; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity | 2007 |